Amar M Salam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7326402/publications.pdf

Version: 2024-02-01

758635 580395 69 702 12 25 citations h-index g-index papers 72 72 72 930 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prevalence of Cardiovascular Risk Factors and 10-Years Risk for Coronary Heart Disease in the United Arab Emirates. Current Diabetes Reviews, 2023, 19, .	0.6	8
2	Opt-Out Consent at Different Levels of Attitude to Organ Donation: A Household Survey in Qatar. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 401-410.	1.1	1
3	Vasoactive pharmacologic therapy in cardiogenic shock: a critical review. Journal of Drug Assessment, 2021, 10, 68-85.	1.1	7
4	From "Heart and Reins" to Clinical Syndromes: Origin and Evolution of Cardio-Renal Disease. Heart Views, 2021, 22, 80-84.	0.1	0
5	Atrial fibrillation in Middle Eastern Arabs and South Asians: a scoping review. Reviews in Cardiovascular Medicine, 2021, 22, 1185.	0.5	1
6	Precipitating factors leading to hospitalization and mortality in heart failure patients: Findings from gulf CARE. Heart Views, 2021, 22, 240.	0.1	1
7	Hypertension in middle eastern arab and south asian patients with atrial fibrillation: From a 20-year hospital registry in Qatar (1990-2010). Heart Views, 2021, 22, 256.	0.1	4
8	Precipitating Factors for Hospitalization with Heart Failure: Prevalence and Clinical Impact Observations from the Gulf CARE (Gulf aCute heArt failuRe rEgistry). Medical Principles and Practice, 2020, 29, 270-278.	1.1	9
9	Clinical presentation and outcomes of peripartum cardiomyopathy in the Middle East: a cohort from seven Arab countries. ESC Heart Failure, 2020, 7, 4134-4138.	1.4	6
10	Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update. Journal of Drug Assessment, 2020, 9, 129-144.	1.1	17
11	Prevalence of socio-demographic and behavioral factors about organ donation in Qatar: A household survey. Qatar Medical Journal, 2020, 2020, 5.	0.2	4
12	PCSK9 monoclonal antibodies: An overview. Heart Views, 2020, 21, 97.	0.1	4
13	Thrombosis Management and Challenges in COVID-19 Patients Presenting with Acute Coronary Syndromes. Heart Views, 2020, 21, 195-208.	0.1	O
14	Racing for COVID-19 Vaccine and Cure: Lessons and Tragedies in Human Subject Research. Heart Views, 2020, 21, 229-234.	0.1	0
15	Demystifying Smoker's Paradox: A Propensity Score–Weighted Analysis in Patients Hospitalized With Acute Heart Failure. Journal of the American Heart Association, 2019, 8, e013056.	1.6	9
16	Circadian Rhythm and ST-Segment Elevation Myocardial Infarction: Insights From the Third Gulf Registry of Acute Coronary Events (Gulf RACE-3Ps). Angiology, 2019, 70, 352-360.	0.8	6
17	Clinical Presentation, Quality of Care, Risk Factors and Outcomes in Women with Acute ST-Elevation Myocardial Infarction (STEMI): An Observational Report from Six Middle Eastern Countries. Current Vascular Pharmacology, 2019, 17, 388-395.	0.8	12
18	Atrial fibrillation in Middle Eastern Arabs and South Asians: Summary of published articles in the Arabian Gulf. Heart Views, 2019, 20, 158.	0.1	3

#	Article	IF	CITATIONS
19	The invention of electrocardiography machine. Heart Views, 2019, 20, 181.	0.1	2
20	Impact of Chronic Kidney Disease on the Presentation and Outcome of Patients Hospitalized With Atrial Fibrillation: Insights From Qatar. Angiology, 2018, 69, 212-219.	0.8	1
21	Acute heart failure presentations and outcomes during the fasting month of Ramadan: an observational report from seven Middle Eastern countries. Current Medical Research and Opinion, 2018, 34, 237-245.	0.9	12
22	Gender Variations in In-Hospital Mortality in Patients Hospitalized With Dizziness: A Retrospective Study. Angiology, 2017, 68, 914-918.	0.8	0
23	Acute myocarditis and pulmonary edema due to scorpion sting. Global Cardiology Science & Practice, 2016, 2016, e201610.	0.3	4
24	Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology. International Journal of Cardiology, 2016, 220, 131-136.	0.8	45
25	Coronary artery disease prevalence and outcome in patients hospitalized with acute heart failure: an observational report from seven Middle Eastern countries. Hospital Practice (1995), 2016, 44, 242-251.	0.5	4
26	Atrial Fibrillation or Flutter During Pregnancy in Patients With StructuralÂHeart Disease. JACC: Clinical Electrophysiology, 2015, 1, 284-292.	1.3	47
27	The influence of female gender on cardiac arrest outcomes: a systematic review of the literature. Current Medical Research and Opinion, 2014, 30, 2169-2178.	0.9	26
28	The prognostic implications of lack of palpitations in patients hospitalised with atrial fibrillation: observations from a 20-year registry. International Journal of Clinical Practice, 2014, 68, 122-129.	0.8	4
29	Impact of religious Ramadan fasting on cardiovascular disease: a systematic review of the literature. Current Medical Research and Opinion, 2013, 29, 343-354.	0.9	83
30	Women hospitalized with atrial fibrillation: Gender differences, trends and outcome from a 20-year registry in a middle eastern country (1991–2010). International Journal of Cardiology, 2013, 168, 975-980.	0.8	18
31	Impact of the 2005 resuscitation guidelines on patient survival after out-of-hospital cardiac arrest: Experience from a 20-year registry in a middle-eastern country. Resuscitation, 2013, 84, e97-e98.	1.3	3
32	Impact of religious fasting on the burden of atrial fibrillation: A population-based study. International Journal of Cardiology, 2013, 168, 3042-3043.	0.8	8
33	Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety. Expert Opinion on Drug Safety, 2013, 12, 53-63.	1.0	6
34	Secular Trends, Treatments, and Outcomes of Middle Eastern Arab and South Asian Patients Hospitalized With Atrial Fibrillation. Angiology, 2013, 64, 498-504.	0.8	9
35	Atrial fi brillation in Middle Eastern Arab and South Asian patients hospitalized with acute myocardial infarction: experience from a 20-year Registry in Qatar (1991–2010). Acta Cardiologica, 2013, 68, 173-180.	0.3	2
36	Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation. Journal of Atrial Fibrillation, 2013, 6, 864.	0.5	1

#	Article	IF	Citations
37	Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial. Expert Review of Cardiovascular Therapy, 2012, 10, 1345-1349.	0.6	4
38	The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727. Expert Opinion on Investigational Drugs, 2012, 21, 1585-1588.	1.9	2
39	Immediate and one-year outcome of patients presenting with Acute Coronary Syndrome complicated by stroke: Findings from the 2ndGulf Registry of Acute Coronary Events (Gulf RACE-2). BMC Cardiovascular Disorders, 2012, 12, 64.	0.7	13
40	Effect of age on treatment, trends and outcome of patients hospitalized with atrial fibrillation: insights from a 20-years registry in a Middle-Eastern country (1991-2010). Aging Clinical and Experimental Research, 2012, 24, 682-90.	1.4	4
41	Contrast-enhanced 64-Section Coronary Multidetector CT Angiography versus Conventional Coronary Angiography for Stent Assessment. Radiology, 2007, 245, 424-432.	3.6	59
42	Drug-Eluting Coronary Stents. Current Problems in Cardiology, 2006, 31, 8-119.	1.1	45
43	The benefits of abciximab questioned in percutaneous coronary interventions following pretreatment with high-dose clopidogrel. Expert Opinion on Investigational Drugs, 2005, 14, 335-338.	1.9	0
44	Acute Myocardial Infarction in the First Trimester of Pregnancy. Asian Cardiovascular and Thoracic Annals, 2005, 13, 175-177.	0.2	1
45	The therapeutic potential of vasopressin in cardiopulmonary resuscitation. Expert Opinion on Pharmacotherapy, 2005, 6, 517-520.	0.9	3
46	The therapeutic potential of vasopressin receptor antagonists in congestive heart failure. Expert Opinion on Investigational Drugs, 2005, 14, 687-691.	1.9	4
47	Evolving role of clopidogrel in acute coronary syndromes. Expert Review of Cardiovascular Therapy, 2005, 3, 977-980.	0.6	0
48	Angiotensin receptor blockers in acute myocardial infarction. Expert Opinion on Investigational Drugs, 2004, 13, 427-430.	1.9	0
49	Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. Expert Opinion on Investigational Drugs, 2004, 13, 707-713.	1.9	1
50	The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials. Expert Opinion on Pharmacotherapy, 2004, 5, 1423-1430.	0.9	6
51	Lipid-Lowering Therapy in Patients with Average Cholesterol and High Cardiovascular Risk, Insights from the Heart Protection Study. Cardiovascular Drugs and Therapy, 2004, 18, 387-389.	1.3	0
52	Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. American Heart Journal, 2004, 147, 815-822.	1.2	100
53	Ximelagatran for stroke prevention in atrial fibrillation. Therapy: Open Access in Clinical Medicine, 2004, 1, 49-52.	0.2	0
54	Ximelagatran for stroke prevention in atrial fibrillation. Therapy: Open Access in Clinical Medicine, 2004, 1 , 49-52.	0.2	0

#	Article	IF	CITATIONS
55	Managing Atrial Fibrillation in Older People: A Comparison of Two Treatment Strategies. Journal of the American Geriatrics Society, 2003, 51, 1806-1807.	1.3	4
56	Acute Myocardial Infarction in a Professional Diver After Jellyfish Sting. Mayo Clinic Proceedings, 2003, 78, 1557-1560.	1.4	27
57	Expanding indications of statins; implications of the Heart Protection Study. Expert Opinion on Investigational Drugs, 2003, 12, 509-513.	1.9	5
58	What are the best first-line antihypertensives: answers and more questions from the ALLHAT study. Expert Opinion on Investigational Drugs, 2003, 12, 879-885.	1.9	1
59	Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study. Expert Opinion on Investigational Drugs, 2003, 12, 1027-1033.	1.9	3
60	Selective aldosterone blockade with eplerenone in patients with congestive heart failure. Expert Opinion on Investigational Drugs, 2003, 12, 1423-1427.	1.9	8
61	Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction. Expert Opinion on Investigational Drugs, 2003, 12, 501-507.	1.9	3
62	Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Expert Opinion on Investigational Drugs, 2003, 12, 1567-1570.	1.9	0
63	Rate control versus rhythm control for the management of atrial fibrillation: the verdict of the AFFIRM trial. Expert Opinion on Investigational Drugs, 2003, 12, 1231-1237.	1.9	3
64	Is there a role for oral blockade of platelet glycoprotein IIb/IIIa receptors in coronary and cerebrovascular disease?. Expert Opinion on Investigational Drugs, 2003, 12, 1709-1712.	1.9	0
65	Rate control versus rhythm control for the management of atrial fibrillation: the verdict of the AFFIRM trial. Expert Opinion on Investigational Drugs, 2003, 12, 1231-1237.	1.9	12
66	Gemella morbillorum endocarditis. Journal of King Abdulaziz University, Islamic Economics, 2003, 24, 1135-7.	0.5	11
67	Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease. Expert Opinion on Investigational Drugs, 2002, 11, 1645-1658.	1.9	11
68	Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 171.	1.5	2
69	The Impact of Diurnal Fasting During Ramadan on Patients with Established Cardiac Disease: A Systematic Review. International Cardiovascular Forum Journal, 0, 15, .	1.1	3